Impedimed Ltd Total Assets

Latest as of June 2026: AU$34.66 Million AUD ≈ $24.52 Million USD

Impedimed Ltd total assets. Based on the latest financial reports, Impedimed Ltd (IPD) holds total assets worth AU$34.66 Million AUD (≈ $24.52 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see IPD stock market capitalisation for the company's overall valuation and market capitalisation.

Total Assets of Impedimed Ltd (2006–2026)

Total assets of Impedimed Ltd from 2006 to 2026. This chart illustrates how Impedimed Ltd's total assets have evolved over time, based on quarterly financial data. See IPD stock price and chart for real-time trading data and today's change.

Impedimed Ltd - Asset Composition Analysis

Impedimed Ltd Total Assets Breakdown (June 2026)

Impedimed Ltd total assets breakdown as of June 2026. Impedimed Ltd's total assets of AU$34.66 Million consist of 67.9% current assets and 32.1% non-current assets.

Asset Category Amount (AUD) % of Total Assets
Cash & Equivalents AU$0.00 44.1%
Accounts Receivable AU$4.68 Million 13.5%
Inventory AU$2.21 Million 6.4%
Property, Plant & Equipment AU$0.00 0.0%
Intangible Assets AU$7.54 Million 21.7%
Goodwill AU$2.63 Million 7.6%

Asset Composition Trend (2006–2026)

This chart illustrates how Impedimed Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Impedimed Ltd current assets vs equity to assess how much short-term liquidity the company maintains relative to its equity base.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Impedimed Ltd's current assets represent 67.9% of total assets in 2026, an increase from 0.0% in 2006.
  • Cash Position: Cash and equivalents constituted 44.1% of total assets in 2026, up from 0.0% in 2006.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 28.0% of total assets, a decrease from 91.0% in 2006.
  • Asset Diversification: The largest asset category is intangible assets at 21.7% of total assets.

Impedimed Ltd Competitors by Total Assets

Key competitors of Impedimed Ltd based on total assets are shown below.

Company Country Total Assets
Shenzhen New Industries Biomedical
SHE:300832
China CN¥9.58 Billion
Double Medical Technology Inc
SHE:002901
China CN¥5.03 Billion
BMC Medical Co. Ltd. A
SHE:301367
China CN¥3.59 Billion
SS Innovations International Inc. Common Stock
NASDAQ:SSII
USA $96.98 Million
Emvision Medical Devices Ltd
AU:EMV
Australia AU$24.94 Million
Sequana Medical NV
BR:SEQUA
Belgium €14.57 Million
Hironic Co. Ltd
KQ:149980
Korea ₩80.01 Billion
DRGEM Corporation
KQ:263690
Korea ₩131.65 Billion

Impedimed Ltd - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 3.81 4.86 3.15
Quick Ratio 3.45 4.71 3.11
Cash Ratio 0.00 3.83 1.41
Working Capital AU$17.35 Million AU$21.85 Million AU$17.52 Million

Impedimed Ltd - Advanced Valuation Insights

This section examines the relationship between Impedimed Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 1.80
Latest Market Cap to Assets Ratio 0.30
Asset Growth Rate (YoY) -16.8%
Total Assets AU$34.66 Million
Market Capitalization $10.37 Million USD

Valuation Analysis

Below Book Valuation: The market values Impedimed Ltd's assets below their book value (0.30x), which may indicate investor concerns about asset quality or future growth.

Significant Asset Reduction: Impedimed Ltd's assets decreased by 16.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.

Annual Total Assets for Impedimed Ltd (2006–2026)

The table below shows the annual total assets of Impedimed Ltd from 2006 to 2026.

Year Total Assets Change
2026-06-30 AU$34.66 Million
≈ $24.52 Million
-16.80%
2025-06-30 AU$41.66 Million
≈ $29.48 Million
-11.34%
2024-06-30 AU$46.99 Million
≈ $33.25 Million
-31.64%
2023-06-30 AU$68.74 Million
≈ $48.64 Million
+17.10%
2022-06-30 AU$58.70 Million
≈ $41.53 Million
+71.61%
2021-06-30 AU$34.20 Million
≈ $24.20 Million
+3.45%
2020-06-30 AU$33.06 Million
≈ $23.39 Million
+46.42%
2019-06-30 AU$22.58 Million
≈ $15.98 Million
-45.68%
2018-06-30 AU$41.57 Million
≈ $29.41 Million
-35.39%
2017-06-30 AU$64.34 Million
≈ $45.53 Million
-28.96%
2016-06-30 AU$90.57 Million
≈ $64.08 Million
+138.86%
2015-06-30 AU$37.92 Million
≈ $26.83 Million
+153.49%
2014-06-30 AU$14.96 Million
≈ $10.58 Million
+26.08%
2013-06-30 AU$11.86 Million
≈ $8.39 Million
-39.51%
2012-06-30 AU$19.61 Million
≈ $13.88 Million
-13.99%
2011-06-30 AU$22.80 Million
≈ $16.14 Million
-8.45%
2010-06-30 AU$24.91 Million
≈ $17.63 Million
+90.18%
2009-06-30 AU$13.10 Million
≈ $9.27 Million
-9.76%
2008-06-30 AU$14.52 Million
≈ $10.27 Million
-33.38%
2007-06-30 AU$21.79 Million
≈ $15.42 Million
+370.60%
2006-06-30 AU$4.63 Million
≈ $3.28 Million
--

About Impedimed Ltd

AU:IPD Australia Medical Devices
Market Cap
$10.37 Million
AU$14.65 Million AUD
Market Cap Rank
#26837 Global
#1235 in Australia
Share Price
AU$0.00
Change (1 day)
+0.00%
52-Week Range
AU$0.00 - AU$0.04
All Time High
AU$1.68
About

ImpediMed Limited, a medical technology company, engages in the development, manufacture, and sale of bioimpedance spectroscopy (BIS) systems and software services in Australia, Europe, North America, and internationally. The company offers SOZO Digital Health Platform which transforms fluid status and tissue composition into insights with a single scan; L-Dex Analysis for Lymphedema, designed fo… Read more